Cholangiocarcinoma Market
Number of pages: 100 | Report Format: PDF | Published date: February 21, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 820.26 million |
|
Revenue Forecast in 2030 |
US$ 1,766.86 million |
|
CAGR |
8.9% |
|
Base Year For Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Therapeutics, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global cholangiocarcinoma market was valued at US$ 820.26 million in 2021 and is expected to register a revenue CAGR of 8.9% to reach US$ 1,766.86 million by 2030.
Cholangiocarcinoma Market Fundamentals
Cholangiocarcinoma, a particular type of cancer, originates in the tiny tubes (bile ducts) that carry the bile, the digestive fluid, throughout the body. At present, the precise cause of cholangiocarcinoma is unknown. The malignant tumor may develop from any part of the bile duct, including the peribiliary glands (intramural and extramural), the gall bladder, and the terminal ductulus (canals of Herring) to the ampulla of Vater. The significant symptom of cholangiocarcinoma includes jaundice, weight reduction, loss of hunger, blood in stool and urine, stomach pain, fever, and itching. When a patient is diagnosed, their condition is typically advanced or incurable, making systemic therapy their only option for treatment. It is well recognized that subgroups also differ in tumor biology and clinical presentation in addition to having different etiological origins. When patients with resectable illnesses initially come, surgery may be curative. However, only a small percentage of them do so with low cure rates.
The patterns of recurrence frequently forbid further curative resection. Additional treatment options include liver transplantation, which historically has not been advised as a treatment for unresectable cholangiocarcinoma due to its high risk of tumor recurrence and short survival. Systemic chemotherapy remains the primary palliative treatment option for patients with unresectable or metastatic cholangiocarcinoma, and the role of adjuvant chemotherapy in cholangiocarcinoma is not well understood. However, chemotherapy has been advised for patients who experience local recurrence following resection of cholangiocarcinoma.
[757547]
Cholangiocarcinoma Market Dynamics
The rising prevalence of cholangiocarcinoma is anticipated to fuel the global cholangiocarcinoma market revenue growth during the forecast period. According to NORD 2021, the USA observes about 12,000 new cases of bile duct cancer every year. More than 9,000 cases are of gallbladder cancers, distal/perihilar cholangiocarcinoma, and 3,000 cases of intrahepatic cholangiocarcinoma.
Patients’ resistance to expensive treatments, prolonged treatment duration, and a high proportion of treatment-related side effects are likely to hinder the revenue growth of the cholangiocarcinoma market.
Cholangiocarcinoma Market Ecosystem
The global cholangiocarcinoma market has been analyzed from three perspectives: therapeutics, distribution channel, and region.
Cholangiocarcinoma Market by Therapeutics
[7547464]
Based on therapeutics, the global cholangiocarcinoma market has been segmented into chemotherapy, targeted therapy, and immunotherapy.
The chemotherapy segment is further sub-segmented into cisplatin, gemcitabine, capecitabine, oxaliplatin, and others (fluorouracil, paclitaxel). The targeted therapy segment is further sub-segmented into pemigatinib, infigratinib, futibatinib, ivosidenib, and others (dabrafenib with trametinib, etc.). The immunotherapy segment is further sub-segmented into durvalumab and pembrolizumab.
Gemcitabine, cisplatin, leucovorin, 5-FU, and other chemotherapy regimens are commonly used for cholangiocarcinoma. The combination of gemcitabine and cisplatin is frequently used as the first-line treatment for cholangiocarcinoma. Gemcitabine is administered intravenously on days 1 and 8 of a 21-day cycle, while cisplatin is administered on day 1. The combination of 5-fluorouracil (5-FU) and leucovorin is also used as a first-line treatment. On days 1-5 of a 28-day cycle, 5-FU is administered as a continuous infusion over 24 hours, while leucovorin is administered on days 1-5. Capecitabine and oxaliplatin are used as second-line treatment options for cholangiocarcinoma. Capecitabine is administered orally twice daily for 14 days, followed by a seven-day break. Oxaliplatin is administered on the first day of each cycle. Another second-line treatment option for cholangiocarcinoma is the combination of gemcitabine and oxaliplatin. Gemcitabine is administered intravenously on days 1 and 8 of a 21-day cycle, while oxaliplatin is administered on day 1. The specific chemotherapy regimen used for cholangiocarcinoma may vary depending on the individual patient’s case as well as other factors, such as the cancer’s stage and location. As a result, the best course of action is determined in consultation with a medical professional.
The accessibility of a wide range of chemotherapeutic agents for the treatment of cholangiocarcinoma and ongoing innovative research on the improvement of chemotherapy through the study of new drugs and new drug combinations through clinical trials are expected to propel revenue growth in the chemotherapy segment. Since the major market players have received regulatory body clearance for their products, the targeted therapy category is anticipated to experience the largest revenue growth in the global cholangiocarcinoma market during the forecast period.
Cholangiocarcinoma Market by Region
Based on the region, the global cholangiocarcinoma market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominates the market due to many ongoing research activities, the rapid and easy production approval process, the growing number of awareness programs, and the increase in public and public-private investment in the region.
The incidence of cholangiocarcinoma is significantly high in countries from Asia Pacific, including Thailand, Japan, China, and Indonesia. This has urged higher treatment demand in the Asia Pacific markets. This trend is anticipated to continue during the forecast period. Cholangiocarcinoma, for instance, is the most common type of liver cancer in Thailand, accounting for up to 60% of cases. The region’s high disease incidence is expected to drive the demand for diagnostic and treatment options in the next few years. Furthermore, rising healthcare expenditure in Asia Pacific is expected to drive the cholangiocarcinoma market even further. As the region’s economies continue to grow, governments are investing more in healthcare infrastructure and services. This will improve access to healthcare services, including cancer diagnosis and treatment. Furthermore, the growing adoption of advanced technologies and treatment options is expected to drive the growth of the Asia Pacific cholangiocarcinoma market. Minimally invasive surgical procedures, such as laparoscopic and robotic-assisted procedures, are becoming more common in the region. This is expected to improve patient outcomes and drive-up demand for similar procedures.
However, the market may face challenges, such as high treatment costs and limited availability of certain therapies in some countries.
Cholangiocarcinoma Market Competitive Landscape
The prominent players operating in the global cholangiocarcinoma market are:
Cholangiocarcinoma Market Strategic Developments
The global cholangiocarcinoma market is expected to register growth at a revenue CAGR of 8.9% during the forecast period from 2022 to 2030.
QED Therapeutics, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and Genentech are among the key players in the global cholangiocarcinoma market.
The chemotherapy segment dominates the global cholangiocarcinoma market.
Asia Pacific is expected to observe the highest revenue growth in the cholangiocarcinoma market during the forecast period from 2022 to 2030.
The global cholangiocarcinoma market was valued at US$ 820.26 million in 2021.
*Insights on financial performance are subject to the availability of information in the public domain